Skip to main content

Table 1 Number of participants screened, enrolled, and finishing follow-up and characteristics at baseline as part of therapeutic efficacy monitoring in Angola, 2015

From: Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015

  Benguela Zaire Lunda Sul
ASAQa ALa ALa DPb DPb ASAQa
Screened, n 445 443 150 223 318 225
 Enrolled, n 101 101 104 102 100 78
 Lost to follow up, n (%) 20 (20) 11 (11) 7 (7) 12 (12) 14 (14) 9 (12)
 Excluded, n (%) 8 (8) 5 (5) 4 (4) 6 (6) 10 (10) 13 (17)
 Reached study endpoint, n (%) 73 (72) 85 (84) 93 (89) 84 (82) 76 (76) 56 (72)
Participant characteristics at baseline
 Median age, years (range) 5.0 (0.7–12) 6.4 (1–12) 3.0 (0.6–5) 2.8 (0.6–5) 2.8 (0.5–5) 3.2 (0.5–5)
 Median weight, kg (range) 16 (6–37) 18 (8–42) 13 (7–19) 13 (6–19) 12 (6–21) 12 (7–18)
 Percent female 40% 40% 51% 53% 42% 58%
 Median day 0 parasitemia, parasites/µL (range) 29,487 (1051–99,507) 20,151 (1003–92,733) 47,766 (2034–195,529) 48,049 (2003–187,777) 7266 (2000–180,903) 16,071 (2000–161,333)
 Median day 0 hemoglobin, g/dL (range) 10.3 (5.2–13.3) 10.2 (5.4–13.5) 10.2 (5.7–13.6) 10.0 (6–13.3) 9.4 (5.1–13.5) 9.2 (5.5–13.6)
  1. ASAQ artesunate–amodiaquine, AL artemether–lumefantrine, DP dihydroartemisinin–piperaquine
  2. a28-day follow-up
  3. b42-day follow-up